S H Bigner

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Darell D. Bigner, Mark T. Brown, Allan H. Friedman et al. · Journal of Clinical Oncology · 1998 · 194 citations

Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med

Henry S. Friedman, P. C. Burger, S H Bigner et al. · Journal of Neuropathology & Experimental Neurology · 1985 · 190 citations · Full text

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

H. S. Friedman, S P Johnson, Qing Dong et al. · PubMed · 1997 · 132 citations

Chemoprevention Strategy, Human Mismatch Repair, Genetics +17

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Mark T. Brown, R. Edward Coleman, Allan H. Friedman et al. · PubMed · 1996 · 99 citations

131I-labeled 81C6, Surgical Oncology, Maximum Tolerated Dose +17

Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.

Xuanmin He, Carol J. Wikstrand, Henry S. Friedman et al. · PubMed · 1991 · 96 citations